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Polymorphism in solids is a common phenomenon in drugs, which can lead to compromised quality 
due to changes in their physicochemical properties, particularly solubility, and, therefore, reduce 
bioavailability. Herein, a bibliographic survey was performed based on key issues and studies related 
to polymorphism in active pharmaceutical ingredient (APIs) present in medications from the Farmácia 
Popular Rede Própria. Polymorphism must be controlled to prevent possible ineffective therapy and/or 
improper dosage. Few mandatory tests for the identification and control of polymorphism in medications 
are currently available, which can result in serious public health concerns.
Uniterms: Polymorphism. Medicines/quality control. Medicines/solubility. Medicines/bioavailability.
O polimorfismo em sólidos é um fenômeno frequente em fármacos e pode levar a problemas na 
qualidade dos medicamentos por alterar suas propriedades físico-químicas, em especial a solubilidade e, 
consequentemente, a biodisponibilidade. Nesse trabalho realizou-se levantamento bibliográfico sobre os 
principais estudos e problemas relacionados ao polimorfismo em fármacos presentes nos medicamentos 
disponibilizados pela Farmácia Popular do Brasil. O polimorfismo deve ser controlado a fim de evitar 
possível ineficácia terapêutica e/ou dosagem inapropriada dos medicamentos. Destacamos que são 
poucos os ensaios obrigatórios para identificação e controle desse fenômeno em medicamentos, o que 
pode acarretar grande problema de saúde pública.
Unitermos: Polimorfismo. Medicamentos/controle de qualidade. Medicamentos/solubilidade. 
Medicamentos/biodisponibilidade.
INTRODUCTION
The Brazilian Governmental Program Farmácia 
Popular Rede Própria was implemented to ensure access 
to low-cost medications that are considered essential 
for health for Brazilian citizens (Brasil, 2003). Some 
medications are manufactured and distributed through this 
nationwide chain. The Farmácia Popular Rede Própria is 
managed by Fundação Oswaldo Cruz (FIOCRUZ). The 
list of available medications is defined by the Ministry of 
Health based on epidemiological studies of the Brazilian 
population (Brasil, 2004). The drugs analyzed herein are 
all from the Farmácia Popular Rede Própria, which is 
hereafter referred to as FPRP.
Drug formulations provided by the FPRP are 
typically solid, which is consistent with the findings of a 
survey published in 2010 that revealed that over 80% of 
all medications are commercialized as tablets (Thayer, 
2010). This predominance of solid drug formulations 
reflects the greater chemical stability of solid state 
compared with liquid state formulations (Nunn et al., 
2005; Lee et al., 2011). Moreover, the development, 
manufacture, transportation, storage and supply of solid 
state formulations are simpler and less expensive in 
comparison to liquid state formulations (Nunn et al., 
2005). However, solid state formulations also present 
challenges, such as polymorphism (Lee et al., 2011). This 
review focuses on the current knowledge of polymorphism 
in solid pharmaceuticals and the potential risk to the 
quality of drug products provided by the FPRP.
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POLYMORPHISM
Definition and General Considerations
Polymorphism occurs when a solid compound exists 
in two or more crystal forms. Polymorphs are compounds 
with an identical chemical composition in which the 
molecules are arranged in at least two different ways in 
the crystalline state (Bilton et al., 1999; Karpinski, 2006; 
Desiraju, 2008; Purohit et al., 2009). In pharmaceutical 
science, however, the term is used to designate several 
solid state forms of drugs and excipients, including 
amorphous forms, solvates, hydrates, salts and co-crystals 
(Aaltonen et al., 2009).
The amorphous form does not possess a defined 
order in its arrangement. Although the amorphous form 
is the most soluble form, it exhibits the lowest stability 
(Haisa et al., 1974; Lowes et al., 1987; Chieng et al., 
2009).
In amorphous and crystalline forms, a solid drug 
may be anhydrous or a solvate/hydrate. When a solid 
form contains a solvent, it is known as a solvate. When 
the solvent is water, it is termed a hydrate (European 
Pharmapoeia, 2008).
Due to the frequent presence of water in the 
environment and its use in solvent blendings during the 
crystallization process, the formation of hydrated drugs 
is common. Because the water molecule is small and able 
to form hydrogen bonds, it is easily incorporated into the 
crystalline lattice of drugs both occupying spaces and 
stabilizing the structure (Gillon et al., 2003).
A survey performed in 1999 on drugs described in 
the European Pharmacopoeia revealed that one-third of the 
808 products listed therein could form hydrates (Griesser, 
2006). In Brazil, drugs commercialized as hydrates include 
the following: amoxicillin trihydrate, ampicillin trihydrate, 
cephalexin monohydrate, sodium dipyrone monohydrate, 
lidocaine hydrochloride monohydrate, meropenem 
trihydrate, methyldopa sesquihydrate, pantoprazole 
sesquihydrate, morphine sulfate pentahydrate, and 
dexamethasone acetate monohydrate (Farmacopeia 
Brasileira, 2010).
In addition to molecular crystals, drug anhydrates 
or solvates/hydrates, co-crystals, and salts also occur. 
Co-crystals are drug solids defined as multicomponent 
molecular crystals in which at least one of the compounds 
is an active pharmaceutical ingredient (API) (Bond, 2007; 
Schultheiss et al., 2009). Salts are considered different 
from co-crystals provided that they are crystals formed 
by ionic multicomponents (Mohamed et al., 2009). The 
FDA has recently published a Regulatory Classification 
of Pharmaceutical Co-Crystals (FDA, 2013) in which 
co-crystal is defined as “Crystalline materials composed 
of two or more molecules within the same crystal lattice” 
and polymorphs as “Different crystalline forms of the 
same drug substance. This may include solvation or 
hydration products (also known as pseudopolymorphs) 
and amorphous forms”.
However, the definitions for these solid forms 
are matters of debate among the scientific community, 
regulatory agencies, and industrial groups, without a 
clear consensus (Schultheiss et al., 2009; Aitipamula et 
al., 2012).
Moreover, a nomenclature for polymorphs has 
not been established. Generally, different polymorphic 
forms of identical molecules are denoted by numerical 
(Carstensen, 2001) or alphabetical sequences; they can 
also be differentiated by means of hydration or solvation 
levels. In general, polymorphs are designated by the 
chronological order in which they have been reported 
(Carstensen, 2001).
The occurrence of polymorphism and its effects on 
solid products are attributed to existing intermolecular 
bonds. These noncovalent bonds, such as hydrogen bonds 
and van der Waals, π-π, and electrostatic interactions, 
determine the arrangement of the molecules in a crystal 
(Desiraju, 1995, 2001; Moulton et al., 2001; Purohit 
et al., 2009). API molecules are produced by atoms 
connected by covalent bonds, whereas crystals consist of 
molecules arranged through intermolecular interactions. 
The differences in these interactions can lead to distinct 
polymorphic forms and vice-versa (Blagden et al., 
2007).
Any variation in the intermolecular arrangement 
of solid materials will alter the physical and chemical 
properties because these characteristics are intrinsically 
determined by its crystalline form, with the possibility of 
affecting bioavailability and stability (Byrn et al., 1999; 
ICH Q6A, 1999; Bauer et al., 2001; Erk et al., 2004; Lee 
et al., 2011).
According to Lee et al., 2011, the properties that 
vary as a consequence of the polymorphic form of the 
active pharmaceutical ingredient are the following: 
a) chemical: chemical reactivity and photochemical 
reactivity; b) kinetic: the rate of dissolution and stability; 
c) mechanical: compactability, hardness, powder 
flow, and friability; d) physical: conductivity, density, 
hygroscopicity, and particle morphology; e) surface: 
interfacial tension, surface area, and surface free energy; 
and f) thermodynamic: chemical potential, free energy, and 
solubility; enthalpy and entropy; heat capacity; melting 
and sublimation; and vapor pressure.
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Challenges for the Pharmaceutical Industry
One of the first reports concerning the influence of 
polymorphism on drugs dates back to 1967 (Aguiar et al., 
1967). In this study, the bioavailability of chloramphenicol 
palmitate in suspension was evaluated in humans, and 
it was concluded that the distinct A and B polymorphic 
forms exhibited not only different dissolution rates but also 
differences in serum levels. Form A, which is more stable, 
did not exhibit adequate bioavailability, whereas form 
B, which is metastable, exhibited greater bioavailability 
(Aguiar et al., 1967).
Although the effects of polymorphism on drugs 
have been known since the 1960s, it was only until the 
case of Norvir® (ritonavir), which is used for the control 
of acquired immunodeficiency syndrome (AIDS), that 
highlighted polymorphism as a serious concern for the 
pharmaceutical industry (Aaltonen et al., 2009). During 
the development of Norvir®, only a single polymorphic 
form was identified. In 1998, several lots of capsules did 
not pass the dissolution test due to the appearance of a 
new polymorphic form (denoted form II) that had formed 
during the manufacturing process, which was more stable 
and not very soluble (Chemburkar et al., 2000; Bauer et 
al., 2001). Thus, the medication was removed from the 
market due to the inability to manufacture the desired 
polymorphic form (form I) (Lee et al., 2011). To resolve 
this issue, Abbott Laboratories was required to spend 
hundreds of millions of dollars with an estimated loss of 
US$250m in sales in 1998 alone (Goldbek et al., 2011).
The reformulation of Norvir® using the more stable 
form required approximately one year, in which patients 
were deprived of this important medication (Peterson et 
al., 2006). The impact on the standard of living of these 
patients caused by drug polymorphism highlights the 
serious consequences of drug polymorphism as a public 
health concern.
A similar situation occurred with rotigotine. 
Originally licensed as a polymorphism-free API, 
Schwarz Pharma commercialized rotigotine in 2006 as a 
transdermal medication to treat the signs and symptoms of 
Parkinson’s disease (Goldbek et al., 2011). Nevertheless, 
in 2008, rotigotine (Neupro®) was removed from the 
market due to the transformation into a less soluble 
polymorphic substance that had crystallized and was not 
absorbed by the skin (Goldbek et al., 2011; FDA, 2008).
Due to its strategic importance for public health, 
medications available in the ‘FPRP’ program (Brasil, 2012) 
were selected for this study to perform a bibliographic 
survey on the occurrence of polymorphism, its possible 
influence on the physicochemical properties of the API and, 
consequently, on the final quality of the pharmaceutical 
formulations.
Bioequivalence and Bioavailability
To reach an expected therapeutic aim, it is imperative 
that pharmaceuticals exist at the expected concentration. 
Considering solid formulations, the medications must 
release the appropriate amount of API at a suitable rate 
for the desired therapeutic effect and be bioequivalent to 
the reference product. Moreover, these formulations must 
exhibit physicochemical stability within their shelf life 
(Aulton, 2005).
The Biopharmaceutical Classification System (BCS) 
may provide useful information to develop strategies to 
control polymorphism because the solubility, dissolution, 
and permeability of an API are determinants of its 
bioavailability. According to the BCS, drugs are subdivided 
into the following four categories: I, high solubility and 
high permeability; II, low solubility and high permeability; 
III, high solubility and low permeability; and IV, low 
solubility and low permeability. A drug is considered to 
have high solubility when its highest recommended dose 
is soluble in 250 mL of aqueous medium in a pH range of 
1-7.5 (Amidon et al., 1995).
Considering that polymorphic forms of an API 
can exhibit different solubility levels, choosing the 
incorrect polymorphic form or the occurrence of a phase 
transition during the manufacture and storage may affect 
the bioavailability and, consequently, the efficacy and 
safety, particularly for drugs for which dissolution is the 
absorption-limiting factor (classes II and IV) (FDA, 2007; 
Llinàs et al.,2008).
When the occurrence of two or more solid forms 
of an API, including polymorphs, is identified during 
the development of a drug, the chosen form is typically 
the most stable (Shingal et al., 2004; Von Raumer, 
Dannappel, Hilfiker, 2012). In addition to being easily 
controllable, the more stable polymorphic form also 
complies with requirements described in the Q6A Guide 
of the International Commission on Harmonization (ICH) 
for solid form selection (Grant et al., 2004).
KNOWN CRYSTAL FORMS OF APIS PROVI-
DED BY THE FPRP
Table I summarizes the different APIs distributed 
by the FPRP as solid pharmaceutical formulations, for 
which the therapeutic class and relevant information 
on polymorphism are also included. Despite 79 of 113 
(69.9%) solid formulations from the FPRP, the number 
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TABLE I - Solid-state forms of Farmácia Popular drugs
API Indication BCS # Stable form* Reference
Acyclovir Antiviral III 6 I
(TSRL inc, 2012; Kristl et al., 1996; Sohn et 
al., 2008; Lutker et al., 2011; Tutughamiarso et 
al, 2012)
Acetylsalicylic Acid Analgesic IV 2 I (TSRL inc, 2012; Klein et al., 1994; Vishweshwar et al., 2005; Bond et al., 2011)
Ibuprofen Analgesic II 2 I
(TSRL inc, 2012; Shankland et al., 1996; Erk 
et al., 2004; Stone et al., 2009; Derollez et al., 
2010)
Acetaminophen Analgesic IV 6 I
(TSRL inc, 2012; Haisa et al., 1974; Naumov 
et al., 1998; McGregor et al., 2002; Parkin et 
al., 2002; Peterson et al., 2002; Fabbiani et al., 
2004)
Albendazole Anthelmintic II 2 II (TSRL inc, 2012; Pranzo et al., 2010)
Mebendazole Anthelmintic II 3 A (TSRL inc, 2012; Rodriguez-Caabeiro et al., 1987; Martins et al., 2009; Ferreira et al., 2010)
Loratadine Antiallergic II 2 ‡ (TSRL inc, 2012; Khunt, 2008; Gala, 1999)
Ferrous sulfate Antianemic † 3 ‡ (Wehner et al., 1976)
Folic acid Antianemic IV 1 Dihydrate (TSRL inc, 2012; Mastropaolo et al.,1980)
Diazepam Antianxiety II 2 ‡ (TSRL inc, 2012; Camerman et al.,1972)
Amiodarone 
hydrochloride Antiarrhythmic II 1 ‡ (Wu et al., 2005; Cody et al., 1989)




Antihypertensive II 1 ‡
(TSRL inc, 2012; Carpy et al., 1985; Yoshida et 
al., 2010)
Amoxicillin Antibiotic IV 1 Trihydrate (TSRL inc, 2012; Boles et al., 1978)
Azithromycin Antibiotic II or IV 3 Dihydrate (TSRL inc, 2012; Blanco M et al., 2005; Montejo-Bernardo et al., 2009)




Antibiotic II 8 IV (monohydrate)
(Otsuka et al., 1983; Stephenson et al., 1998; 
Kennedy et al., 2003; Kasim et al., 2004; 
Aguiar et al., 2011)
Ciprofloxacin Antibiotic III 3 II (hydrate)
(TSRL inc, 2012; Turel et al., 2003; Fabbiani 
et al., 2008; Fabbiani et al., 2009; Fabbiani et 
al., 2011)
Doxycycline Antibiotic IV 2 ‡ (TSRL inc, 2012; Legendre et al., 2012)
Erythromycin Antibiotic IV 4 Dihydrate
(TSRL inc, 2012; Fukumori et al., 1983; 
Stephenson et al., 1997; Miroshnyk et al., 
2006)
Sulfamethoxazole Antibiotic IV 4 III (hemihydrate)
(TSRL inc, 2012; Maury et al., 1985; Hartauer 
et al., 1992; Takasuka et al.,2001; Price et al., 
2005; Fioritto et al., 2007)
Sulfasalazine Antibiotic II 2 ‡ (TSRL inc, 2012; Bilton et al., 1999; Filip et al., 2001)
Trimethoprim Antibiotic IV 1 ‡ (TSRL inc, 2012; Koetzle et al., 1976)
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API Indication BCS # Stable form* Reference
Carbamazepine Anticonvulsant II 6 Dihydrate
(TSRL inc, 2012; Himes et al., 1981; Rebou 
et al., 1981; Lowes et al., 1987; Lisgarten et 
al., 1989; Lang et al., 2002; Grzesiak et al., 
2003; Harris et al., 2005; Gelbrich et al., 2006; 
Kogan et al., 2008; Arlin et al., 2011)
Phenytoin Anticonvulsant II 1 I (TSRL inc, 2012; Nokhodchi et al., 2003)
Phenobarbital Anticonvulsant IV 13 A
(TSRL inc, 2012; Otsuka et al., 1993; Platteau 
et al., 2005; Zencirci et al., 2009; Zencirci et 
al., 2010)
Amitriptyline 
hydrochloride Antidepressant I 1 I (TSRL inc, 2012; Klein et al., 1994)
Fluoxetine 
hydrochloride Antidepressant I 1 I (TSRL inc, 2012; Robertson et al., 1988)
Glibenclamide Antidiabetic II 1 I (TSRL inc, 2012; Byrn et al., 1986)
Metformin 
hydrochloride Antidiabetic III 2 A (TSRL inc, 2012; Childs et al., 2004)
Metoclopramide 
hydrochloride Antiemetic II or IV 3 ‡ (TSRL inc, 2012; Pabón et al., 1996)
Clonazepam Antiepileptic † 1 I (Chananont et al., 1979)
Ketoconazole Antifungal II 2 I (enantiomer +)
(Peeters et al., 1979; Peeters et al., 2004; Wu et 
al., 2005)
Fluconazole Antifungal III 4 I
(TSRL inc, 2012; Alkhamis et al., 2002; Caira 
et al., 2004; Chandavarkar, Jindai, Kulkarni, 
2011)
Miconazole Nitrate Antifungal † 3 ‡ (Pedersen et al., 1993; Peeters et al., 2004)
Promethazine 
hydrochloride Antihistamine I 2 ‡ (TSRL inc, 2012; Borodi et al., 2012)
Atenolol Antihypertensive III 2 I (TSRL inc, 2012; Esteves De Castro et al., 2007)
Captopril Antihypertensive III 2 I (B) (TSRL inc, 2012; Haoming et al., 1985; 
Fekete, 1997; Zhenhong et al., 2011)
Enalapril maleate Antihypertensive I 2 II (TSRL inc, 2012; Précigoux et al., 1986; Evjolfsson, 2003; Kiang et al., 2003)
Losartan Antihypertensive III 5 I
(TSRL inc, 2012; Campbell et al., 1997; 
Dolitzky et al., 2004; Wu et al., 1993; 
Fernández et al., 2002; Tessler et al., 2004)
Methyldopa Antihypertensive III 1 ‡ (TSRL inc, 2012; Neuman et al., 1984)
Nifedipine Antihypertensive II 3 A= I= α (TSRL inc, 2012; Uekama et al., 1992; Grooff et al., 1997; Gunn et al., 2012)
Propranolol 
hydrochloride Antihypertensive I 3 II
(TSRL inc, 2012; Bartolomei et al., 1999; 
Bredikhin et al., 2004)
Simvastatin Antilipemic II 3 I (TSRL inc, 2012; Cejka et al., 2003; Husak et al., 2010)
Biperiden Antiparkinsonian I 1 I (TSRL inc, 2012; Codding, 1986)
Carbidopa Antiparkinsonian I ‡ ‡ (Lindenberg et al., 2004)
TABLE I - Solid-state forms of Farmácia Popular drugs (cont.)
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API Indication BCS # Stable form* Reference
Levodopa Antiparkinsonian I 2 I (TSRL inc, 2012; Mostad et al., 1970; Mostad et al., 1971; Howard et al., 1995)
Benserazide 
hydrochloride Antiparkinsonian † ‡ ‡ ‡
Metronidazole Antiprotozoal IV 1 ‡ (TSRL inc, 2012; Galván-Tejada et al., 2002)
Chlorpromazine Antipsychotic II 2 Anhydrous (TSRL inc, 2012; McDowel, 1969; Klein et al., 1986)
Haloperidol Antipsychotic II 1 I (TSRL inc, 2012; Prasanna et al., 2001)
Omeprazole Antiulcer † 1 ‡ (Ohishi et al., 1989)
Ranitidine 
hydrochloride Antiulcer III 4 II
(TSRL inc, 2012; Ngooi et al., 1994, 
Agatonovic-Kustrin et al., 1999; Hempel et al., 
2000; Chieng et al., 2006)
Oseltamivir 
phosphate Antiviral I or III 1 ‡ (TSRL inc, 2012; Kang et al., 2012)
Salbutamol sulfate Bronchodilator I 3 I (Lindenberg et al., 2004; Lulla et al., 2011, Rao et al., 2011; Palacio et al., 2007)
Allopurinol Chronic gout treatment IV 1 I (TSRL inc, 2012; Prusiner et al., 1972)
Ethinyl estradiol Contraceptive I 1 Hemihydrate (TSRL inc, 2012; Guguta et al., 2008)
Levonorgestrel Contraceptive I 2 ‡ (TSRL inc, 2012; Chang, Chen, 2009)
Norethisterone Contraceptive I 1 ‡ (Lindenberg et al., 2004; Reisch et al., 1993; Shikii et al., 2005)
Furosemide Diuretic IV 3 I (TSRL inc, 2012; Babu et al., 2010)
Hydrochlorothiazide Diuretic IV 2 ‡ (TSRL inc, 2012; Leech et al., 2008)
Prednisone Glucocorticoid I 1 ‡ (Vogt et al., 2007; Suitchmezian et al., 2008)
Azathioprine Immunosuppressant IV 2 ‡ (TSRL inc, 2012; Cook, Bugg, 1975; Acharya,1984)
Alendronate sodium Inhibitor of bone resorption III 13 ‡
(TSRL inc, 2012; Kieczykowski et al.,1990; 
Vega et al., 1996; Finkelstein et al., 2004; 
Asnani et al., 2009)
Isosorbide 
mononitrate Vasodilator I 2 ‡ (Fotaki, Vertzoni, 2010; Kanters et al., 1993)
#: minimum number of known crystal structures; *: Room temperature; †: Unclassified; and ‡: Not reported.
Note: For the overall polymorphic forms, neither salts and solvates without pharmaceutical application nor co-crystals were 
considered.
TABLE I - Solid-state forms of Farmácia Popular drugs (cont.)
of different solid APIs is 65. This difference is due to 
the availability of more than one dosage for an identical 
API. Table I also includes the BCS class, known crystal 
structures and correct polymorph reported in the literature 
that is present in the medication for each API.
The Cambridge Structural Database (CSD, 2011) 
and Inorganic Crystal Structure Database (ICSD, 2002) 
was used to analyze crystalline structures by entering 
the compound name, molecular form, and chemical 
structure. Information on patents and indexed journals 
in the electronic databases SciFinder© (2012) and Web 
of Science© (2012) were also collected. Compound 
structures were included as single component forms, 
hydrates, salts, and solvates with pharmaceutical 
application. Biopharmaceutical classification was 
obtained at the Therapeutic System Research Laboratories, 
which is managed by Amidon et al., 2012 (TSRL inc 
2012). Furthermore, a search was performed using the 
aforementioned electronic databases by combining 
the terms “name of the compound in English” and 
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“polymorph” in the free search of databases. Articles 
that discussed solid state chemical polymorphism 
were included; articles that discussed other types of 
polymorphism were excluded.
Table I indicates that phenobarbital and alendronate 
sodium are the APIs with the most reported polymorphic 
crystal structures (11 forms each) followed by cephalexin 
(8 forms) and acetaminophen/carbamazepine/acyclovir 
(6 forms each). A total of 168 crystal structures were 
found for the 65 APIs listed in Table I, which resulted 
in a mean value of 2.67 polymorphs per API. Figure 1a 
illustrates that 42 (65%) of the 65 APIs exhibit two or more 
polymorphs of known crystal structure. Only 21 (32%) 
APIs do not exhibit more than one reported crystal form. 
However, it is important to emphasize that in this review, 
only polymorphs deposited in the CSD© and ICSD© or 
in articles indexed in SciFinder© and Web of Science© 
were considered. The revision work also indicates that 
no crystal structure is known for 2 (3%) APIs listed in 
Table 1. For some APIs, the thermodynamically stable 
form (or preconized polymorphic form) is reported in 
the literature. This result is also summarized in Table I 
and is illustrated in Figure 1b. Noteworthy is the number 
of APIs (24, 37%) without studies indicating the correct 
crystal form, of which 13 (54%) have two or more known 
polymorphic crystal structures.
Figures 1c and 1d show the BCS classification of 
the 65 solid APIs available at the FPRP, illustrating that 31 
(48%) possess low solubility (classes II and IV). Figure 2 
shows the number of APIs with “unknown”, “only one”, 
and “two or more” crystal structures per BCS class. For 
21 (68%) of the 31 class II and IV APIs (low solubility), 
two or more crystal structures have been reported. For 17 
(68%) of the 25 class I and III APIs (high solubility), two 
or more polymorphic structures have been reported.
Despite 41 (63%) APIs (Table 1) with more than one 
reported crystal structure, as previously mentioned, there 
are studies concerning the influence of polymorphism 
on drug performance for only 22 (14.3%). Problems 
related to either the efficacy or the manufacture caused by 
polymorphism have been reported, i.e., for mebendazole, 
carbamazepine, estradiol, and acetaminophen.
Albendazole and Mebendazole
The antiparasitic albendazole and mebendazole 
are among the low solubility drugs with reported 
polymorphism. Albendazole is commercialized in form I 
(metastable), which is the most soluble form. Both forms 
I and II are stable under storage conditions; however, 
much care is required to control the form because of the 
possibility of undesirable polymorphic phase conversion 
in this API (Pranzo et al., 2010).
Mebendazole exhibits polymorphic forms A, B, and C, 
which differ in their biopharmaceutical and physicochemical 
properties. Polymorph C is the pharmaceutically preferred 
form due to its adequate aqueous solubility (Rodriguez et 
al., 1987; Charoenlarp et al., 1993). Form A is the most 
FIGURE 1. Statistical features of the 65 APIs available as solid formulations at the FPRP. (a) The number of different crystal 
structures (polymorphs when there are more than one structure); (b) the types of solid forms expected to be present in the solid 
formulation; (c) the distribution in the BCS (I = high permeability, high solubility; II = high permeability, low solubility; III = low 
permeability, high solubility; and IV = low permeability, low solubility); and (d) the distribution in the BCS indicating the APIs 
with high solubility (classes I and III) and low solubility (classes II and IV).
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FIGURE 2. The number of different crystal structures distributed 
in the four classes of the BCS for the 65 APIs that are available 
as a solid formulation at the FPRP.
stable, less soluble form that is considered therapeutically 
ineffective (Rodriguez et al., 1987). In a clinical study with 
958 children, the efficacy of polymorph A did not differ 
from the placebo (Charoenlarp et al., 1993). Costa et al. 
(1991) have shown that polymorph B is more soluble than 
polymorph C. Therefore, polymorph B should be avoided 
or a strategy to ensure the proper dosage must be developed 
to enable the drug to exert the desired effect. Form C, thus, 
recommended for oral use, is metastable and, in solution, 
may crystallize as the more stable form A (Rodriguez et 
al., 1987; Agatonovic-Kustrin et al., 2008). Moreover, 
regarding stability, the presence of small quantities of form 
A in tablets results in a rapid increase of transformation 
into other polymorphic forms. Four analyzed trademark 
drugs presented traces of form A, and, in most of them, the 
shelf life was reduced to less than a month. These products 
also failed to comply with the acceptance criteria of the 
United States Pharmacopoeia (USP) and the Food and Drug 
Administration (FDA) in dissolution assays (Brits et al., 
2010). Therefore, the anthelmintic efficacy of mebendazole 
is highly dependent on the polymorphism (Martins et al., 
2009).
Quality control routine tests that may distinguish 
among polymorphic forms include the dissolution 
assay, IR spectroscopy, thermogravimetric analyses, 
and primarily powder X-ray diffraction measurements 
(Liebenberg et al., 1998). Nevertheless, it was observed 
that the mebendazole dissolution assay described in USP 
25 did not distinguish among the three polymorphic 
forms. The recommended dissolution medium was 0.1 M 
hydrochloride acid containing sodium lauryl sulfate (SLS). 
The solubility difference among the polymorphs had 
been masked with the inclusion of the surfactant, and the 
removal of SLS from the dissolution medium resolved the 
polymorphic forms (Swanepoel et al., 2003).
Despite this example, the USP 34 (2011) continues 
to recommend a dissolution medium that contains SLS. 
Therefore, much attention should be directed at quality 
control methods that are able to discriminate between 
polymorphic forms and that the polymorphic form present 
in the medication is the recommended form. In this respect, 
characterization using powder X-ray diffraction is very 
useful.
In 2005, an analysis of the raw materials and 
drug products containing mebendazole in the Brazilian 
market revealed the following alarming results: the 
expected form C was not found in any analyzed raw 
material, USP reference standard included. From the 10 
analyzed medications, five contained polymorph A, three 
contained polymorph C, and two contained a mixture 
of polymorphs B and C, with B as the majority. At the 
time the study was published, the mebendazole reference 
brand (manufactured by Abbott Laboratories) was altered. 
Polymorph C was not detected in this new reference 
medication, which also contained different polymorphs 
in different lots (Froehlich et al., 2005).
Furosemide
Another low solubility drug that exhibits problems 
related to the dissolution assay in official compendia 
is the diuretic furosemide. When the solubilities of 
furosemide polymorphs are compared, the metastable 
form II is found to be the most soluble (Matsuda et al., 
1990). This API has been observed to undergo photolytic 
degradation from which the metastable forms suffer more 
than the thermodynamically stable form I (Matsuda et 
al., 1990; Villiers et al.1992). To differentiate furosemide 
polymorphic forms in pharmaceutical formulations, 
several dissolution mediums were tested, which resulted 
in a recommended medium at pH 2.2 due to its ability to 
differentiate the commercialized form (form I) from the 
other forms (II and III) (Maggio et al., 2009).
Considering the diuretic furosemide as an 
example, the in vitro dissolution assay is an excellent 
tool to differentiate polymorphic forms and identify 
polymorphic phase transitions. Provided the test 
anticipates bioavailability and physical stability, it can 
evaluate the quality of a medication (Yu et al., 2003; Raw 
et al., 2004).
Therefore, methods that are described in official 
compendia must be carefully considered because, 
as observed with mebendazole, the recommended 
dissolution test for furosemide does not discriminate 
among forms (United States Pharmacopeia, 2011). Thus, 
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the development of methods that are able to differentiate 
polymorphic forms is essential for the quality control of 
medications, particularly for low solubility drugs (Bonfilio 
et al., 2012).
Fluconazole
Fluconazole confirms the high frequency of hydrate 
occurrence in APIs. Fluconazole exists as a mixture of 
forms I and II and fluconazole monohydrate (Park et al., 
2007). The solubility order among the polymorphs of this 
API is II (metastable) > I > monohydrate (Park et al., 2010), 
and forms I and II convert into the monohydrate when 
dissolved in water (Park et al., 2010). Polymorph II has 
been found to absorb humidity and form the monohydrate 
phase from both the environment and the excipient during 
either the storage phase or the manufacturing phase 
(Chandavarkar, Jindai, Kulkarni, 2011).
Acyclovir
The acyclovir in pharmaceutical formulations is 
present as a hydrate (polymorph V) (Kristl et al., 1996; 
Lutker et al., 2011). Unexpectedly, the hydrated form of 
acyclovir solubilizes more rapidly than the anhydrous 
form (Kristl et al., 1996; Stephenson et al., 1997), which 
is explained by the high thermodynamic stability and low 
hygroscopicity of the anhydrous form (Kristl et al., 1996).
Cephalexin, Erythromycin, Ciprofloxacin, 
Sulfamethoxazole, and Digoxin
A tendency to form hydrates is also observed in 
the antibiotics cephalexin, erythromycin, ciprofloxacin, 
and sulfamethoxazole. In pharmaceutical preparations, 
monohydrated cephalexin is the predominant polymorphic 
form (Aguiar et al., 2011). Cephalexin is also found in 
the dihydrated form, which, at room temperature, rapidly 
loses one molecule of water to form the monohydrated 
cephalexin (Kennedy et al., 2003). A similar phenomenon 
occurs with erythromycin, which is commercialized in its 
more stable and less soluble dihydrated form. This API 
loses its water molecules at relatively low temperature 
(71 °C) (Fukumor et al., 1983).
As for ciprofloxacin, the exposure of form I 
(anhydrous) to a relative humidity higher than 90% leads 
to the appearance of form II (hydrate), which is observed 
when an aqueous suspension of form I is prepared (Mafra 
et al., 2012).
For sulfamethoxazole, form II converts to the 
hemihydrate (form III) more rapidly than form I. In the 
solubility assay, a phase transition was not observed for 
form II, whereas form I converted to the hemihydrate 
under identical conditions (Fioritto et al., 2007).
Micronization with supercritical antisolvent has led 
to an increase in the sulfamethoxazole dissolution rate and 
has caused the phase transition of polymorph I to II, with 
a solubility ratio of 1.2 (Pudipeddi et al., 2005; Chang et 
al., 2008).
Studies revealed that for digoxin, the grinding process 
leads to amorphization (Florence et al., 1976). Storage 
of the amorphous form at room temperature results in a 
reduction in solubility (Chiou et al., 1979), which is a great 
concern considering that this antiarrhythmic has a narrow 
therapeutic window. Thermal stress of digoxin also results 
in polymorphic phase transitions (Eberhard et al., 1983).
Carbamazepine
The impact of polymorphism has been extensively 
studied on the anticonvulsant carbamazepine, highlighting 
its impact on product quality. In 1988, a clinical failure was 
reported for Tegretol® tablets (carbamazepine), likely due 
to the polymorphic phase transition from the anhydrous to 
the dihydrate form (Lee et al., 2011). Moreover, there are 
several reports of variability in the dissolution profile of 
commercially available carbamazepine tablets (Davidson, 
1994; Meyer et al., 1992, 1998; Al-Zein et al., 1999; Lake 
et al., 1999; Mittapalli et al., 2008).
Carbamazepine is one of the few APIs for which the 
recommended polymorphic form is described in official 
compendia. Although such compendia determine form 
III for medical preparations, they do not define limits for 
the other forms (European Pharmacopeia, 2008; British 
Pharmacopeia, 2009; United States Pharmacopeia, 2011), 
and the manufacture of this API does not always result in 
pure crystalline phases (Rustichelli et al., 2000; Lang et al., 
2002; Grzesiak et al., 2003; Quist et al., 2008; Javadzadeh 
et al., 2009; Diao et al., 2012; Wang et al., 2012), which 
emphasizes the need to develop methods to quantify the 
contamination of form III with other polymorphic forms 
(Kipouros et al., 2005).
A mixture of polymorphic forms has been observed 
in commercial samples of carbamazepine raw material 
(Šehić et al., 2010; Flicker et al., 2011). As expected, 
these polymorphs exhibit different dissolution rates. 
Form III converts to carbamazepine dihydrate (a less 
soluble form) more rapidly than form I, which critically 
affects the solubility and bioavailability of pharmaceutical 
preparations (Kobayashi et al., 2000).
When pure form III samples are compared, the effect 
of particle size on the dissolution rate is counterintuitive, 
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i.e., a larger amount of small-sized particles results in 
a slower carbamazepine dissolution rate, which occurs 
because the narrow shape of these particles enables 
the conversion to the dehydrate (Flicker et al., 2011). 
Micronization of carbamazepine by expansion in 
supercritical solution appears to increase the solubility 
of the drug, although this process may lead to a phase 
transition (Bolten et al., 2012).
Phenobarbital
Six  of  the  polymorphic  forms of  another 
anticonvulsant, phenobarbital (A, B, C (monohydrate), D 
(dioxane solvate), E (hemihydrate) and F), were evaluated. 
The order of the dissolution rate among the forms is F > B 
> E > C > A > D, and the order of the hardness among the 
tablets containing them is D > A > C > E > B = F (Otsuka 
et al., 1994).
Under isothermal conditions (45 °C), phenobarbital 
stability was as follows: A, B, and F forms were stable 
at 0 and 75% relative humidity, whereas C, D, and E 
forms underwent transformation during storage, with the 
transformation rate of form D as the fastest (Otsuka et 
al., 1993).
Acetylsalicylic Acid
The possibility of the occurrence of polymorphism 
in acetylsalicylic acid (ASA) antiinflammatory and 
analgesic products has been investigated since the 1960s 
(Tawashi, 1968). It was only in 2005 that polymorphism 
was verified in this API, in which it was found that form 
II (metastable) coexists with form I (Vishweshwar et 
al., 2005). Subsequently, form II was isolated, and its 
conversion into form I occurs at room temperature, which 
is accelerated by mechanical grinding (Varughese et al., 
2011).
Acetaminophen
Acetaminophen, which is another analgesic and 
antithermic drug, is an example of manufacturing problems 
associated with polymorphism (Snider et al., 2004). Form 
II (metastable), in contrast to form I (stable), can be used 
in the manufacture of tablets, which is advantageous 
because the process is simpler and less expensive (Di et al., 
1996; Nichols et al., 1998). To manufacture medications 
containing form I, commercially available agglutinant 
excipients are required, which increases the cost (Di et al., 
1997; Nichols et al., 1998). Because the dissolution rate is 
similar for both form II and commercialized form I tablets, 
a possible transformation does not lead to problems with 
bioavailability (Di et al., 1996).
Verapamil Hydrochloride, Enalapril, Losartan, and 
Propranolol
For antihypertensive drugs that contain verapamil 
hydrochloride, studies were performed at temperatures 
varying from 25 °C to 750 °C using several analytical 
techniques, and it was found that this API did not exhibit 
polymorphic forms at the evaluated conditions (Yoshida 
et al., 2010).
In the studies on enalapril, form II was observed 
to be much less stable than form I in tablets containing 
an identical amount of sodium hydrogen carbonate 
(Eyjolfsson, 2002). The increased ratio of sodium 
hydrogen carbonate in the tablet containing form II and the 
presence of desiccant in the blister packaging significantly 
decreased its degradation (Eyjolfsson, 2003).
Losartan antihypertensive form I is thermo-
dynamically more stable and less soluble than form II 
at room temperature, and form II may convert to form 
I during storage (Wu et al., 1993; Crocker et al., 1997).
Both forms I and II of another antihypertensive, 
propranolol, are stable at room temperature even after 
grinding and compression. Polymorph I (metastable) is 
34% more soluble than form II (commercially available) 
(Bartolomei et al., 1999).
Ranitidine, Glibenclamide, and Estradiol
Ranitidine, which is prescribed for the treatment of 
ulcers, exhibits polymorphic forms I and II with similar 
solubility and bioavailability (Bawazir et al., 1998; 
Parkin et al., 2002). Notwithstanding, a slight difference 
in stability was observed between these forms, and phase 
transitions can occur via water absorption, mechanical 
strength (Carstensen et al., 1995; Foster et al., 1998; 
Chieng et al., 2006) and during storage (Madan et al., 
1994).
Glibenclamide form I is the most stable with a 
melting point of 175.4 °C and that of form II of 151.0 °C. 
Every form (I, II, III, and IV) was found to be stable below 
zero or 100% relative humidity, with form III as the most 
soluble (Sohn et al., 1997).
A polymorphism effect was also found for estradiol. 
Transdermal adhesives, which contain this drug, formed 
crystals during storage. The crystals belonged to different 
estradiol polymorphs and also to the polymeric adhesive 
(Variankaval et al., 1999).
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QUALITY CONTROL OF POLYMORPHIC 
SOLID FORMS
Single crystal and powder X-ray diffraction 
techniques are the most suitable and more utilized tools 
to study and characterize polymorphs in pharmaceutical 
solids because they provide unequivocal proof of 
either polymorphism existence or polymorphism 
occurrence (FDA, 2007). Powder X-ray diffraction 
is feasible for application in the quality control of 
polymorphism in capsules, tablets, and pastes, among 
others. For this purpose, the API must be crystalline and 
be present at a concentration greater than 5% (w/w) in the 
formulation, which is the commonly adopted detection 
limit for phase quantification using PXRD techniques. The 
pharmaceutical formulation can be analyzed after minimal 
or no pretreatment of the sample without a requirement 
to separate the API from the excipients because most 
excipients are not detected by X-rays. Moreover, it is 
possible to simultaneously identify more than one API in 
the formulation (Phadnis et al., 1997).
Others important techniques such as microscopy, 
thermal analysis (e.g., differential scanning calorimetry, 
thermal gravimetric analysis, and hot-stage microscopy), 
and spectroscopy (e.g., infrared [IR], Raman, and solid-
state nuclear magnetic resonance [ssNMR]) are also 
commonly used in the quality control of polymorphism in 
drugs. Diffraction, spectroscopic, and thermal techniques 
are considered complementary in the study of polymorphs. 
Polymorphic transitions can also be detected using drug 
product dissolution testing (FDA, 2007) because the test 
is demonstrably able to differentiate different forms.
Despite the vast accumulated scientific knowledge 
on the effects of phase transitions in APIs in the solid state, 
crystalline form characterization assays are not included 
in most monographs described in official compendia. 
Conversely, the FDA published the Guidance for Industry 
of FDA - ANDAs: Pharmaceutical Solid Polymorphism 
Chemistry, Manufacturing, and Controls Information 
that provides recommendations for the monitor and 
control of polymorphs in drug substances and/or drug 
products (FDA, 2007). However, in USP 35-NT 30, 
assays on powder X-ray diffraction are described in 
only 15 monographs from the 4,500 monographs that 
include APIs, excipients and drug products (United States 
Pharmacopeia, 2012).
CONCLUSION
For many drugs present in medications that are 
available at the FPRP, according to the best of the 
authors’ knowledge, there are few studies that correlate 
polymorphism to possible influences on drug solubility 
as well as its clinical impact. Therefore, the existence 
of polymorphs may potentially be an important source 
of variation in pharmaceutical properties, which can 
cause problems concerning the stability, solubility 
and, consequently, efficacy and bioavailability of 
drug products. Relatively simple quality control tests 
allow the differentiation of polymorphs. However, 
the identification of the polymorphic phase is not a 
mandatory test for the large majority of drugs. Thus, 
more commitment is necessary by regulatory and quality 
control authorities to monitor polymorphism not only 
for FPRP medications but also for all commercial drugs. 
This monitoring includes the control of polymorphism in 
raw materials, manufacturing steps and finished products 
by the end of the shelf life of the drug. In this manner, 
possible public health concerns linked to polymorphism 
in medicines can be avoided.
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